Foster City, California – In a significant move poised to reshape the landscape of cancer treatment, Gilead Sciences announced today a definitive agreement to acquire Arcellx for a total equity value of $7.8 billion. The acquisition, expected to close in the second quarter of 2026, centers on gaining full control of anito-cabtagene autoleucel (anito-cel), a promising CAR T-cell therapy for multiple myeloma, and the innovative D-Domain technology platform developed by Arcellx. This deal marks Gilead’s largest acquisition since the $21 billion purchase of Immunomedics in 2020, signaling a continued commitment to expanding its oncology portfolio and securing cutting-edge immunotherapies.
The agreement stipulates a cash payment of $115 per share to Arcellx stockholders, representing a 68% premium over the 30-day volume-weighted average price. Arcellx shareholders will receive a contingent value right (CVR) of $5 per share, tied to the achievement of specific revenue targets for anito-cel. This strategic acquisition builds upon a successful collaboration initiated in 2022 between Kite, a Gilead company, and Arcellx, focused on the co-development and co-commercialization of anito-cel. The move allows Gilead to eliminate future profit-sharing, milestone payments, and royalties associated with the therapy, potentially boosting long-term profitability.
Gilead’s Bold Bet on CAR T-Cell Therapy
Anito-cel, a BCMA-directed CAR T-cell therapy, has demonstrated encouraging results in clinical trials for patients with relapsed or refractory multiple myeloma – a cancer of plasma cells. Multiple myeloma remains a challenging disease to treat, with many patients experiencing relapse and diminishing responses to existing therapies. The U.S. Food and Drug Administration (FDA) has already accepted the Biologics License Application (BLA) for anito-cel, with a Prescription Drug User Fee Act (PDUFA) target date of December 23, 2026, for a potential decision. Gilead anticipates that anito-cel could become a foundational treatment option, potentially utilized even in earlier lines of therapy.
CAR T-cell therapy involves modifying a patient’s own immune cells to recognize and attack cancer cells. Current CAR T-cell therapies can be associated with significant side effects and logistical complexities. Anito-cel has shown a predictable and manageable safety profile in clinical studies, addressing key challenges associated with existing treatments. Analysts at RBC Capital Markets have suggested that anito-cel may offer a better safety profile compared to Carvykti, a leading CAR T-cell therapy developed by Johnson & Johnson and Legend Biotech, which generated approximately $1.9 billion in sales in 2025. CNBC reported that several analysts believe anito-cel has the potential to become a “multi-billion dollar product” for Gilead.
The D-Domain Technology Platform
Beyond anito-cel, the acquisition provides Gilead with access to Arcellx’s proprietary D-Domain technology platform. This platform is designed to enhance the specificity and binding affinity of immunotherapies, potentially leading to more effective and targeted cancer treatments. The D-Domain technology could be applied to the development of future CAR T-cell therapies and other immunotherapeutic approaches, expanding Gilead’s pipeline and strengthening its position in the rapidly evolving field of oncology. The platform’s ability to improve the precision of immune cell targeting is a key driver of the deal’s value.
Financial Implications and Market Reaction
Gilead anticipates that the acquisition of Arcellx will be accretive to earnings per share beginning in 2028, assuming the successful approval of anito-cel. The elimination of future financial obligations to Arcellx, including profit-sharing and milestone payments, is expected to improve Gilead’s operating margins in the cell therapy space. The $7.8 billion price tag represents a significant investment for Gilead, reflecting the company’s confidence in the potential of anito-cel and the D-Domain platform.
The market reacted strongly to the news, with Arcellx shares soaring 77.9% to $114.06 in morning trading following the announcement, nearly matching the $115 per share offer price. Reuters reported that the stock closed at $113.75. Gilead’s stock, however, experienced a more muted response, closing down 1.04% at $149.83. Market observers attribute this to concerns about the short-term impact on Gilead’s balance sheet and the regulatory hurdles remaining before the PDUFA decision date.
Daniel O’Day, Chairman and CEO of Gilead Sciences, emphasized the strategic rationale behind the acquisition, stating that it will “maximize the long-term potential of anito-cel” and accelerate its development and commercialization. Rami Elghandour, CEO of Arcellx, echoed this sentiment, describing the combination as a “logical step to maximize global access to innovative therapies.”
Looking Ahead: Regulatory Review and Commercialization
The next critical milestone for anito-cel is the FDA’s decision on the BLA, scheduled for December 23, 2026. If approved, Gilead will be responsible for the commercialization of the therapy, leveraging its established infrastructure and expertise in oncology. The company will also continue to advance the development of the D-Domain platform, exploring its potential applications in other cancer types and immunotherapeutic approaches. The successful integration of Arcellx and the realization of anito-cel’s potential will be key to Gilead’s long-term growth strategy in the competitive oncology market.
The acquisition of Arcellx underscores the growing trend of consolidation in the cell therapy space, as pharmaceutical companies seek to secure access to innovative technologies and promising therapeutic candidates. The demand for effective cancer treatments remains high, and CAR T-cell therapy represents a rapidly evolving field with the potential to transform the lives of patients with previously untreatable cancers. Gilead’s investment in anito-cel and the D-Domain platform positions the company at the forefront of this innovation.
Key Takeaways:
- Gilead Sciences is acquiring Arcellx for $7.8 billion, gaining full control of the promising CAR T-cell therapy anito-cel.
- The FDA is expected to decide on the approval of anito-cel for multiple myeloma by December 23, 2026.
- Arcellx’s D-Domain technology platform offers potential for developing more effective and targeted immunotherapies.
- The acquisition is expected to be accretive to Gilead’s earnings per share beginning in 2028, contingent upon anito-cel’s approval.
The coming months will be crucial as Gilead awaits the FDA’s decision on anito-cel. Investors and healthcare professionals will be closely watching the progress of this promising therapy and its potential impact on the treatment of multiple myeloma. We will continue to provide updates on this developing story as they become available.
What are your thoughts on Gilead’s acquisition of Arcellx? Share your perspectives in the comments below, and please share this article with your network.